130 related articles for article (PubMed ID: 28024110)
21. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
22. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
23. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions.
Ensani F; Nematizadeh F; Irvanlou G
Pol J Pathol; 2011; 62(2):95-100. PubMed ID: 21866465
[TBL] [Abstract][Full Text] [Related]
25. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
[TBL] [Abstract][Full Text] [Related]
27. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
Kundu UR; Krishnamurthy S
Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
[TBL] [Abstract][Full Text] [Related]
28. A panel of markers for identification of malignant and non-malignant cells in culture from effusions.
Carneiro FP; Muniz-Junqueira MI; Pittella-Silva F; Carneiro MV; Takano GHS; Vianna LMS; De Andrade LB; De Castro TMML; Peres I; Dos Santos Borges TK; Ferreira VM; Motoyama AB
Oncol Rep; 2017 Dec; 38(6):3538-3544. PubMed ID: 29039588
[TBL] [Abstract][Full Text] [Related]
29. The cell adhesion molecule, E-cadherin, distinguishes mesothelial cells from carcinoma cells in fluids.
Schofield K; D'Aquila T; Rimm DL
Cancer; 1997 Oct; 81(5):293-8. PubMed ID: 9349517
[TBL] [Abstract][Full Text] [Related]
30. Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.
Athanassiadou P; Gonidi M; Liossi A; Petrakakou E; Nakopoulou L; Zerva C; Athanassiades P
Pathol Oncol Res; 2000; 6(2):100-3. PubMed ID: 10936783
[TBL] [Abstract][Full Text] [Related]
31. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
Morgan RL; De Young BR; McGaughy VR; Niemann TH
Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
[TBL] [Abstract][Full Text] [Related]
32. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
33. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
34. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
35. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
36. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
[TBL] [Abstract][Full Text] [Related]
37. Cytological study of serous effusions with the aid of tumour markers.
Ray K; Mittal S; Gupta H; Jain M
J Indian Med Assoc; 1999 Jan; 97(1):11-2, 19. PubMed ID: 10549179
[TBL] [Abstract][Full Text] [Related]
38. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
Ascoli V; Bosco D; Carnovale Scalzo C
Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
[TBL] [Abstract][Full Text] [Related]
39. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
40. Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology.
Patil B; Shivkumar V; Gangane N
Indian J Pathol Microbiol; 2018; 61(1):90-93. PubMed ID: 29567891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]